Recce Pharmaceuticals Share Price and Company Fundamentals

0.000 (0.000%)
52 week
0.74 - 1.34

Last traded: Last Friday at 6:10 AM

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesPharmaceutical research and development.
Industry / SectorBiotechnology / Healthcare
Mailing addressAurora Place Level 25 88 Phillip Street Sydney NSW 2000 Australia
Phone / Fax61 2 9256 2571 /


Recce Pharmaceuticals does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Recce Pharmaceuticals.

NameTitleAgeTotal Pay
Mr. James Hamilton-Bray Graham GAICDCEO, MD & Exec. Director349.81k
Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci)Chief Scientific Director & Exec. Director272.55k
Dr. Justin WardPrincipal Quality Chemist & Exec. Director161.2k
Mr. Arthur KollarasPrincipal Engineer & Head of Manufacturing131.2k
Mr. Justin ReynoldsChief Financial Officer
Mr. Daniel Astudillo B.A., B.Com., M.B.A.Head of Marketing
Prof. Philip SuttonMember of Clinical Advisory Committee & Head of Helicobacter Pylori Devel. Program
Mr. Alistair McKeough BA, LLB, LLMCompany Sec.

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Recce Pharmaceuticals is 166.83M and its enterprise value is 146.08M. The enterprise value to revenue ratio of RCE is 89.22.

The RCE's stocks Beta value is 1.44 making it 44% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Recce Pharmaceuticals (RCE)

Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions

1. What is Recce Pharmaceuticals's Stock Symbol?

Recce Pharmaceuticals trades on ASX under the ticker symbol "RCE".

2. What is Recce Pharmaceuticals's stock price today?

One share of RCE stock can currently be purchased for approximately $0.96.

3. How can I contact Recce Pharmaceuticals?

Recce Pharmaceuticals's mailing address is Aurora Place Level 25 88 Phillip Street Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9256 2571.

4. What is Recce Pharmaceuticals's official website?

The official website of Recce Pharmaceuticals is

5. Which share registry manages Recce Pharmaceuticals's stock?

Recce Pharmaceuticals's stock is managed by AUTOMIC REGISTRY SERVICES.